Catalyst
Slingshot members are tracking this event:
PDUFA date set to Jan 18 2019 for Immunomedics' (IMMU) IMMU-132( sacituzumab govitecan) for triple-negative breast cancer patients
- Source Link:
- http://www.immunomedics.com/pdfs/SGEN.pdf
Do you think this event is important to the companies below? How will it affect their stock price?
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 17, 2019
Occurred Source:
https://globenewswire.com/news-release/2019/01/18/1701746/0/en/Immunomedics-Receives-Complete-Response-Letter-From-FDA-for-Sacituzumab-Govitecan-Biologics-License-Application.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fda Approval, Immu-132, Commercial Launch, Triple Negative Breast Cancer
